Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation

BayerBayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI). The company announced that new clinical data for gadoquatrane, Bayer's investigational macrocyclic gadolinium-based compound currently in Phase III development, will be presented at the 2023 Radiological Society of North America (RSNA) Annual Meeting - taking place from November 26 to 30, 2023, in Chicago, USA. Bayer also announced the results of a recently published paper on the cost effectiveness of supplemental screening methods for women with dense breasts in the U.S., to provide greater certainty around the clinical and economic benefits of supplemental screening methods. In addition, Bayer announced four collaboration agreements with the aim to further expand the offering on its medical imaging platform Calantic™ Digital Solutions.

The activities at RSNA reflect Bayer’s commitment as a leading company in key areas of radiology to address today’s industry challenges and accelerate innovation for the benefit of patients and their clinicians, including harnessing the vast potential of artificial intelligence (AI).

Fostering innovation in Radiology AI

In more than 30 panel discussions, Bayer's AI team composed jointly of experts from both Calantic™ Digital Solutions and Blackford Analysis as well as external thought leaders, will share insights to help healthcare providers, hospital administrators and developers advance their AI strategy, discussing topics like regulatory challenges in the field of AI in medical imaging, app selection, and how to leverage clinical utility frameworks to assess return on investment (ROI). Partner companies from both Bayer and Blackford will present various app approaches and solutions.

While Blackford provides infrastructure and access to a rich clinical application (ClinApp) ecosystem focused on imaging and analytics, Bayer’s own platform Calantic™ Digital Solutions which is building on technology from Blackford and adding additional workflow and analytics components, delivers access to applications for medical imaging, including those enabled by AI - coming with the value proposition to support diagnosis and increase the throughput of medical imaging examinations. On the occasion of RSNA 2023, Bayer also announced that it will partner with radiology AI technology providers Perspectum Limited, Brainomix Limited, Qure.ai, and Imagine Software - with the aim to further expand the offering on its medical imaging platform CalanticTM Digital Solutions.

In addition, Bayer is offering various tech talks, including pilot "Spark Tank Sessions" where app companies at an early stage can learn new ways to refine their value proposition, and get feedback such as optimal workflow and commercialization pathways from an expert panel. Calantic SPARK, Bayer’s accelerator program for medical imaging app developers to further foster innovation in radiology AI, will showcase its partners Imagine Software (Within Health) and Scanslated. Bayer's Calantic SPARK is a targeted program to help radiology AI startups of all stages get to market faster by offering advice spanning medical, regulatory, reimbursement expertise, and market access - thereby enabling commercialization and distribution through Calantic™ Digital Solutions.

Blackford, the global strategic AI platform and solutions provider that was acquired by Bayer under the well-established company’s arm’s length model, continues to expand its AI portfolio and global strategic relationships in advance of RSNA. The AI portfolio available via the Blackford Platform now includes over 100 applications from 40 separate partner vendors. Blackford has also recently entered into partnerships with global medical imaging provider Philips, healthcare interoperability provider Rhapsody and enterprise imaging provider Mach7 to support their respective journeys into AI solution provision.

Taking a glimpse at a radiology clinic of the future

Reflecting Bayer's overall RSNA 2023 theme "Let's Envision the Future of Radiology", the Experience Center at Bayer’s main booth (#2519) will offer visitors an immersive tour through a radiology clinic of the future. Here they can discover the company's digital, integrated, disease-oriented solutions across the entire radiology workflow - through the eyes of a patient. The Experience Center includes 21 different stations along the journey, each with interactive content, including Augmented Reality (AR).

About Radiology at Bayer

As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence - from innovative products to high-quality services - to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by Artificial Intelligence (AI). Bayer's radiology products generated close to €2bn sales in 2022. Based on the company’s ambition to outperform the radiology market’s average annual growth rate of 5 percent by 2030, Bayer is highly committed to research and development, which includes leveraging AI and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction - from diagnosis to care.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

Most Popular Now

AI in Personalized Cancer Medicine: New …

The application of AI in precision oncology has so far been largely confined to the development of new drugs and had only limited impact on the personalisation of therapies. New...

AI can Predict Brain Cancer Patients…

Artificial Intelligence (AI) can predict whether adult patients with brain cancer will survive more than eight months after receiving radiotherapy treatment. The use of the AI to successfully predict patient outcomes...

Max Planck Institute for Informatics and…

The Max Planck Institute for Informatics and Google deepen their strategic research partnership. With additional financial support from the U.S. IT company, the "Saarbrücken Research Center for Visual Computing, Interaction...

JMIR Medical Informatics Invites Submiss…

JMIR Publications has announced a new section titled, "AI Language Models in Health Care" in JMIR Medical Informatics. This leading peer-reviewed journal is indexed in PubMed and has a unique...

Paper Calls for Patient-First Regulation…

Ever wonder if the latest and greatest artificial intelligence (AI) tool you read about in the morning paper is going to save your life? A new study published in JAMA...

Could ChatGPT Help or Hurt Scientific Re…

Since its introduction to the public in November 2022, ChatGPT, an artificial intelligence system, has substantially grown in use, creating written stories, graphics, art and more with just a short...

Evaluating the Performance of AI-Based L…

A new study evaluates an artificial intelligence (AI)-based algorithm for autocontouring prior to radiotherapy in head and neck cancer. Manual contouring to pinpoint the area of treatment requires significant time...

Making AI a Partner in Neuroscientific D…

The past year has seen major advances in Large Language Models (LLMs) such as ChatGPT. The ability of these models to interpret and produce human text sources (and other sequence...

Chapman Scientists Code ChatGPT to Desig…

Generative artificial intelligence platforms, from ChatGPT to Midjourney, grabbed headlines in 2023. But GenAI can do more than create collaged images and help write emails - it can also design...

DMEA nova Award: Wanted - Visionary Solu…

9 - 11 April 2024, Berlin, Germany. The DMEA nova Award is being presented at DMEA 2024 for the first time. The award honours a digital health startup for an outstanding...

New Digital Therapy Reduces Anxiety and …

A therapist-guided digital cognitive behavioural therapy reduced distress in 89 per cent of participants living with long-term physical health conditions, a new King's College London study finds. Researchers at the Institute...

Europe's Digital Health Industry Me…

9 - 11 April 2024, Berlin, Germany. In just over two months, from 9 to 11 April 2024, DMEA, Europe's leading event for digitalisation of healthcare, will gather digital health experts...